Date: 2016-02-15
Type of information: Collaboration agreement
Compound:
Company: Charles River Laboratories (USA - MA) Eisai (Japan)
Therapeutic area: Technology - Services - Neurological diseases - Parasitic diseases
Type agreement: collaboration R&D
Action mechanism:
Disease: neurological diseases, malaria
Details: * On February 15, 2016, Eisai and Charles River Laboratories announced that they have signed a collaboration agreement which will see Charles River scientists work at Eisai's research and development facilities in Hatfield, UK.
The collaboration will involve Charles River supporting Eisai scientists from Japan, USA and the UK on a range of synthetic and medicinal chemistry projects, including those seeking novel treatments for neurological diseases.
Charles River scientists will also participate in a medicinal chemistry project to discover new antimalarial drugs with activity against drug resistant strains of disease, which could potentially address this area of unmet medical need in malaria treatment. This work is in collaboration with the GHIT Fund (Global Health Innovative Technology Fund) and Medicines for Malaria Venture, and builds upon earlier research by Eisai which has focused on malaria and neglected diseases to improve access to medicines in developing countries.
Financial terms:
Latest news:
